A Phase 2 Study of SHR-1210 (PD-1 Antibody) in Combination With Apatinib or Chemotherapy (FOLFOX4 or GEMOX) in Subjects With Advanced Primary Liver CancerPLCor Biliary Tract Carcinoma (BTC)
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2018
At a glance
- Drugs Camrelizumab (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Rivoceranib
- Indications Biliary cancer; Liver cancer
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 24 Jul 2018 The protocol was amended to include patients with Biliary Tract Carcinoma (BTC) and GEMOX regimen.
- 24 Jul 2018 Planned number of patients changed from 36 to 152.
- 24 Jul 2018 Planned End Date changed from 1 Dec 2018 to 1 Mar 2019.